New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:41 EDTTSROTESARO price target lowered to $43 from $57 at RW Baird
Baird lowered its price target on TESARO citing the potential for a significant new competitor for one of its key drugs. The firm believes its Rolapitant P3 commercial thesis remains intact but worry the its competitor's formulation may be closer to reality than previously thought. Shares remain Outperform rated but cautious.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
06:25 EDTTSROMedivation removed from Focus List at Citigroup
Subscribe for More Information
06:23 EDTTSROCiti ups TESARO price target to $79, adds to focus list
Subscribe for More Information
February 20, 2015
05:53 EDTTSROTESARO price target raised to $50 from $44 at Mizuho
Mizuho raised its price target for TESARO shares to $50 citing increased confidence and market opportunity for niraparib following the company's Q4 results. The firm expects approval for rolapitant in Q3 and reiterates a Buy rating on the stock.
February 19, 2015
16:13 EDTTSROTESARO reports Q4 EPS ($1.33), consensus ($1.03)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use